SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Heightened geopolitical tensions in the Middle East, particularly concerning Iran and Israel, are sparking intense debate around SPY, as initial futures show a relatively muted reaction despite fears of broader conflict. The community is divided between those anticipating a major market crash and others expecting an aggressive 'buy the dip' rebound, fueled by observations of a historically resilient market and rising oil prices.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions in the Middle East and concerns over potential oil supply disruptions fuel a sharply divided community sentiment, with some predicting a market crash while others anticipate a swift "buy the dip" rebound.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions, particularly concerning the Strait of Hormuz, fuel community speculation about a significant surge in oil prices and a potential short squeeze, with many comparing its current trajectory to previous parabolic runs during geopolitical conflicts.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending amidst rising geopolitical conflicts, fueling speculation about increased demand for its drone and counter-UAS technology from global defense sectors, while the community actively discusses the potential for a short squeeze and upcoming contract announcements.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as escalating geopolitical tensions and news of a standoff between the Pentagon and AI provider Anthropic are driving conversation around its critical role in defense AI. The community is actively discussing how this reinforces Palantir's position as a trusted, model-agnostic platform, leading to strong bullish sentiment and calls for significant upward movement.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is trending due to better-than-expected earnings and highly optimistic guidance for its next-generation 800G and 1.6T products, driven by surging demand from AI data centers. The community is sharply divided, with bulls highlighting aggressive revenue projections and analyst upgrades, while bears raise concerns about the company's profitability, valuation, and a recently announced at-the-market stock offering.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is trending as escalating Middle East tensions lead to market expectations of surging oil prices and potential supply disruptions, driving community speculation for a strong short squeeze due to the stock's high short interest and recent debt reduction.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is surging amid escalating Middle East tensions, with the community actively anticipating a significant rise in oil prices due to concerns over potential strikes on Iran and disruptions to the critical Strait of Hormuz. Many view energy stocks as a strong play as global supply risks intensify.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as recent geopolitical uncertainty boosts interest in defense technology, while community discussions also focus on the company's participation in the "Drone Dominance" program and upcoming "Innovation Day," creating both high expectations for future contracts and ongoing debate about management's execution.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending as the community hotly debates escalating Middle East tensions and threats to global oil supply routes, anticipating a significant price surge while also considering the counter-effect of Venezuela's potential oil market reentry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research

Zacks Research upgraded shares of MoonLake Immunotherapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, meeting the...

Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Stock analysts at Lifesci Capital raised their Q4 2025 EPS estimates for shares of MoonLake Immunotherapeutics in a report released on...

Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price

Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00

BTIG Research increased their price objective on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a "buy" rating in a report on Monday...

MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins

MoonLake Immunotherapeutics (NASDAQ:MLTX) used its Investor Day presentation to outline updates across its clinical portfolio for sonelokimab (SLK), a tri-specific nanobody designed to inhibit IL-17A...

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish...

<ul class="summary-bullets"><li>President Donald Trump announced over the weekend that global tariffs would rise from 10% to 15%.&nbsp;</li><li>Traders are also watching last-ditch nuclear negotiations with Iran scheduled in Geneva later this week.&nbsp;</li><li>Nvidia earnings later this week could define the next leg of the market.</li></ul>U.S. stock futures were sharply lower early Monday as investors grappled with a renewed tariff uncertainty, rising geopolitical tensions with Iran, and awaited Nvidia's big earnings report later this week. Last week’s momentum is being tested by President Donald Trump’s announcement over the weekend of a hike in global tariffs from 10% to 15%, which came a day after the Supreme Court struck it down as ‘anti-American.’The markets are also watching last-ditch nuclear talk attempts with Iran in Geneva this Thursday, amidst reports that the U.S. is considering significant military action if diplomacy fails.&nbsp;As of 3:00 a.m. ET on Monday, Nasdaq futures fell 0.6%, the S&amp;P 500 and Dow futures declined 0.5%, while Russell 2000 futures were down nearly 1%.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘bearish’ from ‘neutral’ last week, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;On the other hand, precious metals have seen a breakout, with gold rising above $5,100 and silver nearing $88/oz.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chip giant reports earnings on Feb 25. Beyond its guidance, all eyes will be on its commentary on AI hype, investments, and sustainability.Netflix (NFLX):&nbsp;The stock is facing potential downward pressure after President Trump threatened consequences if board member Susan Rice is not removed. This adds another layer of uncertainty as it pursues its bid for Paramount Skydance (PSKY).&nbsp;Honeywell (HON):&nbsp;It has entered into an amended deal to acquire Johnson Matthey’s Catalyst Technologies business for $1.8 billion.Vanda Pharmaceuticals (VNDA):&nbsp;The US FDA has approved Bysanti for bipolar I disorder and schizophrenia.Moonlake Immunotherapeutics (MLTX):&nbsp;Positive Phase 2 data for its spinal disease drug have led to strong after-hours gains. Traders will be watching this stock closely as we head into a new week.&nbsp;Immunity Bio (IBRX):&nbsp;This biotech stock continues to garner retail attention. Executive chairman Patrick Soon-Shiong&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us">teased</a> a detailed three-year expansion roadmap, with a detailed press release expected on Monday.&nbsp;Deere &amp; Co (DE):&nbsp;One of the most actively traded stocks last week saw a downgrade to ‘Underperform’ from Jefferies, with a target price of $550. The analyst believes it is already ‘discounted a full recovery’ and trades at steep valuations.&nbsp;Rolls-Royce (RYCEY): The company is reportedly preparing a buyback program of up to €1.5 billion.Other tickers trending on Stocktwits at the time of writing included Capricor Therapeutics (CAPR), Kraft Heinz Co (KHC), Oklo Inc (OKLO), and Ardelyx (ARDX), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of factory orders at 10:00 am ET. They will also be watching for commentary from Fed Governor Christopher Wallace before the bell today.&nbsp;On the earnings radar, investors will be watching for the quarterly reports from Domino’s Pizza (DPZ), GeneDX (WGS), Freshpet (FRPT), and Dominion Energy (D), among others, before the bell&nbsp;today. Also watch out for Hims &amp; Hers (HIMS), Keysite Technologies (KEYS), and Diamonback Energy (FANG) that report after market close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 

Equity

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 


<ul class="summary-bullets"><li>Phase 2 S-OLARIS trial data showed 81% of patients improved within 12 weeks, meeting the primary endpoint.</li><li>Imaging and biomarker results confirming reduced spine inflammation, while no new safety issues were identified.</li><li>MoonLake enters Investor Day with funding in place into the second half of 2027, supported by $394 million in cash.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. (MLTX) surged over 10% in overnight trading on Sunday ahead of Monday’s Investor Day, as newly released clinical data for its experimental spine disease drug reignited investor interest after a volatile year marked by a major setback.<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> jumped over 3% on Friday to hit $18.77, but ended 0.3% lower in after-hours trading.&nbsp;<h2 class="st-heading-2">Phase 2 Trial In Spine Disease Meets Primary Endpoint&nbsp;</h2>On Sunday, the company reported positive topline results from a Phase 2 clinical trial of Sonelokimab (SLK) in patients with axial spondyloarthritis, a chronic inflammatory disease that causes severe back pain, stiffness, and progressive loss of mobility.&nbsp;MoonLake said its Phase 2 S-OLARIS trial showed that 81% of patients treated with SLK saw clear improvement in their condition within 12 weeks. The trial met its primary endpoint, using the same standard doctors and regulators rely on to judge whether new treatments for this disease reduce pain, inflammation, and limits on daily movement.MoonLake reported that more than 80% of patients also showed clinically important improvement on additional disease activity measures by Week 12. These clinical gains were supported by imaging results, with MRI scans showing reductions in inflammation inside affected joints.PET imaging further showed a reduction in both inflammation and osteoblast activity within the sacroiliac joints by Week 12. Osteoblast activity is a key driver of irreversible bone formation and progressive loss of mobility in axial spondyloarthritis. Tests on patients’ blood and tissue showed that the drug quickly and consistently reduced the inflammation signals that drive the disease to worsen over time.The company said the safety profile of SLK in the S-OLARIS trial was consistent with previous studies and that no new safety signals were identified.&nbsp;<h2 class="st-heading-2">Cash Position Extends Runway Into 2027</h2>MoonLake reported that it ended 2025 with $394 million in cash, cash equivalents, and short-term marketable securities. The company said this, combined with proceeds from a recent $75 million equity raise, is expected to fund operations into the second half of 2027.The company also announced an amended debt facility with Hercules Capital, including a $25 million drawdown and up to $400 million in additional non-dilutive funding available to support future needs.<h2 class="st-heading-2">Why The Data Matters&nbsp;</h2>The Phase 2 readout marks a positive development for MoonLake following a sharp selloff in September 2025, when one of its Phase 3 trials in a separate skin disease indication failed to meet its primary endpoint. That result triggered a roughly 90% collapse in the stock price over two sessions and sparked a securities class-action lawsuit filed in December.MoonLake will host its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-heads-into-investor-day-with-fda-momentum/cZRjp7xR4wl">Investor Day</a> on Feb. 23, with presentations from its CEO, chief scientific officer, and CFO, followed by an open Q&amp;A session. The company will also discuss the outcomes of its recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding hidradenitis suppurativa, including next steps related to label strategy and the planned biologics license application submission.&nbsp;Additionally, the company plans to share an interim analysis of the continued response to SLK beyond Week 16 from the Phase 3 Vela trials in adult patients with hidradenitis suppurativa, as well as interim data from the Vela-Teen Phase 3 trial in adolescent patients.MoonLake said the Investor Day will also include an update on its financial position and a review of key 2026 catalysts. These include upcoming data releases from the Phase 3 Izar trials in psoriatic arthritis, as well as the planned Phase 3 development program in palmoplantar pustulosis.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MLTX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_34534e245f.webp" alt="mltx ss.png" width="961" height="144"><figcaption>MLTX sentiment and message volume as of February 22 | Source: Stocktwits</figcaption></figure>One user said, “I didn't think were were getting the financials until Wednesday. &nbsp; Looks very positive to me.&nbsp; Tomorrow should be epic, shorts might wanna cover ASAP.”<stembedurl>https://stocktwits.com/DerekVtx/message/645569026</stembedurl>Another user said, “Today had amazing news, tomorrow morning will have many announcements but there are many more to follow. This is like top 10 roadmaps for any drug company right now”&nbsp;<stembedurl>https://stocktwits.com/LouKojak/message/645565865</stembedurl>MLTX stock has risen 42% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown

 Investors are now turning to Monday’s Investor Day for regulatory clarity, pipeline updates, and key 2026 catalysts.

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given New $12.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada boosted their price target on shares of MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a "sector perform" rating in a research note on Friday...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$17.51
Prev Close	$17.68
Open	$17.49
Dividend Yield	0.00%
50-Day Moving Average	$15.56
Beta	0.57
Avg. Volume	3.66M
PE Ratio	-4.97

52-Week High	$62.75
52-Week Low	$5.95
Market Capitalization	$1.24B
EPS (Annual)	-$3.53
Price to Book	4.10
Revenue Per Employee	$0.00

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLTX News

MLTXMoonLake Immunotherapeutics